Cargando…
Impact of tumour size measurement inter-operator variability on model-based drug effect evaluation
PURPOSE: During oncology clinical trials, tumour size (TS) measurements are commonly used to monitor disease progression and to assess drug efficacy. We explored inter-operator variability within a subset of a phase III clinical trial conducted from August 1995 to February 1997 and its impact on dru...
Autores principales: | Lombard, Aurélie, Mistry, Hitesh, Chapman, Sonya C., Gueoguieva, Ivelina, Aarons, Leon, Ogungbenro, Kayode |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125250/ https://www.ncbi.nlm.nih.gov/pubmed/32170415 http://dx.doi.org/10.1007/s00280-020-04049-5 |
Ejemplares similares
-
Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data
por: Wendling, Thierry, et al.
Publicado: (2016) -
Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of the DNA damage response pathway
por: Hodson, David, et al.
Publicado: (2023) -
A “middle‐out approach” for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) models
por: Yau, Estelle, et al.
Publicado: (2023) -
Investigation of simplified physiologically‐based pharmacokinetic models in rat and human
por: Yau, Estelle, et al.
Publicado: (2023) -
Model‐Based Drug–Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy
por: Cleary, Yumi, et al.
Publicado: (2021)